Literature DB >> 24179893

The effect of carvedilol on blood glucose levels in normal albino rats.

Suresha R N1, Ashwini V, Pragathi B, Kalabharathi H L, Satish A M, Pushpa V H, Jayanthi M K, Snehalatha P.   

Abstract

BACKGROUND: Carvedilol is a commonly used drug in hypertension, congestive heart failure in diabetics. It has moderate calcium channel blocking property in addition to α1 and non selective β antagonistic activity. Though some studies bring forth the beneficial effects of Carvedilol in cardiovascular comorbidities in diabetes, there is no consensus on its effects on glycaemic levels. AIMS: To evaluate the effect of oral Carvedilol administration for 5 days on blood glucose levels in normal albino rats through Oral Glucose Tolerance Test.
MATERIAL AND METHODS: Twelve adult albino rats of either sex weighing between 150 - 200 g were selected from central animal facility and randomly divided into 2 groups - Control [Distilled water (1ml/rat orally)] and Test (0.8mg/kg body weight orally) and the respective drugs were administered over 5 days. Following overnight fasting, on the fifth day 1 hour after the last dose of the respective drug, OGTT was performed. The CBG (Capillary Blood Glucose) levels were measured at 0 min, glucose (2g/kg body weight) dissolved in water was administered to all the rats orally. The blood sample from tail vein (obtained by tail snipping) at 60 and 150 minutes were analysed for CBG levels using a standardized glucometer. STATISTICAL ANALYSIS: Data was presented as Mean ± SEM. One way ANOVA, independent samples t-test, non-parametric tests, percentages and cross tabs were used in the analysis of data within the same group and between different groups when required.
RESULTS: Carvedilol group showed higher CBG levels at all time intervals of OGTT as compared to the Control group i.e., 0, 60 and 150 minutes, the highest being (103.8±5.029 )mg/dl at 60 minutes and was statistically significant. Carvedilol group however showed lesser inter-interval variation compared to the Control group at the same time intervals respectively but was statistically insignificant.
CONCLUSIONS: Carvedilol has hyperglycaemic potential when given orally for 5 days in normal albino rats. Though it may be beneficial in diabetics for various comorbid conditions, the glycaemic control may worsen during its use in subjects with prediabetes, diabetes, high risk diabetes.

Entities:  

Keywords:  Calcium channel blocker; Carvedilol; Diabetes mellitus; Drug induced hyperglycaemia; Hyperglycaemia; Oral glucose tolerance test

Year:  2013        PMID: 24179893      PMCID: PMC3809632          DOI: 10.7860/JCDR/2013/6435.3346

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.

Authors:  E Breda; M K Cavaghan; G Toffolo; K S Polonsky; C Cobelli
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

Review 2.  Localized calcium influx in pancreatic beta-cells: its significance for Ca2+-dependent insulin secretion from the islets of Langerhans.

Authors:  L S Satin
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

3.  Glucose, blood pressure, and cardiovascular risk.

Authors:  Ranee R Lleva; Silvio E Inzucchi
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-03-01

Review 4.  The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives.

Authors:  Lei Chen; Dianna J Magliano; Paul Z Zimmet
Journal:  Nat Rev Endocrinol       Date:  2011-11-08       Impact factor: 43.330

5.  In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.

Authors:  A J Nichols; A C Sulpizio; D J Ashton; J P Hieble; R R Ruffolo
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

6.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

7.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Authors:  George L Bakris; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Jackson T Wright; Rosemary Oakes; Mary Ann Lukas; Karen M Anderson; David S H Bell
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

8.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

Review 9.  Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.

Authors:  G Z Feuerstein; R R Ruffolo
Journal:  Eur Heart J       Date:  1996-04       Impact factor: 29.983

10.  Adverse prognostic significance of new diabetes in treated hypertensive subjects.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Claudia Borgioni; Roberto Gattobigio; Lucia Filippucci; Silvia Norgiolini; Costanza Bracco; Carlo Porcellati
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

View more
  2 in total

1.  Carvedilol improves glucose tolerance and insulin sensitivity in treatment of adrenergic overdrive in high fat diet-induced obesity in mice.

Authors:  Linh V Nguyen; Quang V Ta; Thao B Dang; Phu H Nguyen; Thach Nguyen; Thi Van Huyen Pham; Trang Ht Nguyen; Stephen Baker; Trung Le Tran; Dong Joo Yang; Ki Woo Kim; Khanh V Doan
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

2.  Improvement in glycemia after glucose or insulin overload in leptin-infused rats is associated with insulin-related activation of hepatic glucose metabolism.

Authors:  Emma Burgos-Ramos; Sandra Canelles; Laura M Frago; Julie A Chowen; Eduardo Arilla-Ferreiro; Jesús Argente; Vicente Barrios
Journal:  Nutr Metab (Lond)       Date:  2016-03-01       Impact factor: 4.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.